New VISICORT study in Frontiers in Immunology

A new study has just been published by VISICORT researchers in the leading open access journal Frontiers in Immunology today, 20 November 2018. The study “Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation” was completed by the National University of Ireland Galway team of Paul Lohan, Nick Murphy, Oliver Treacy, Kevin Lynch, Maurice Morcos, Bingling Chen, Aideen E. Ryan, Matthew D. Griffin and Thomas Ritter.

The study shows for the first time that intravenous administration of third-party allogeneic mesenchymal stromal cells (MSC from neither the new cornea recipient nor the cornea donor) results in distinct immune modulatory effects that overcome pre-existing anti-donor immunity to prolong rejection-free survival of corneal allografts in a laboratory model of high-risk corneal transplantation. The experimental cell therapy regimen described in the paper appears to be compatible with prior cryo-preservation and with co-administration of a relevant immunosuppressive drug. These findings open the door to clinical translation of “off-the-shelf” allogeneic MSC products for recipients of high-risk corneal transplants who continue to suffer from very poor long-term graft survival rates. The results of this experimental study have formed the basis of a regulatory submission for the VISICORT Phase Ib clinical trial in patients receiving a second or greater transplant who are at high risk of rejection. This trial will determine the safety and feasibility of co-administration of allogeneic MSC and MMF in the setting of high-risk corneal transplantation.

VISICORT publishes in Frontiers in Immunology

The paper ‘Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?’ is based on the work of Dr Paul Lohan, Dr Oliver Treacy, Prof Matthew Griffin, Prof Thomas Ritter and Dr Aideen Ryan of the National University of Ireland Galway. The publication appears in the November 24, 2017, edition of Frontiers in Immunology. This research was funded by VISICORT, amongst other sources. Read the entire manuscript here.

Front. Immunol., 24 November 2017

https://doi.org/10.3389/fimmu.2017.01626

VISICORT partners involved in exciting new stem cell project

VISICORT partners NUI Galway, Orbsen, and Pintail are involved in NEPHSTROM, a new European project, which was launched last week. NEPHSTROM involves eleven partners from Ireland, the UK, Germany, and the Netherlands, and has received €6 million funding under the European Union’s Horizon 2020 funding programme. NEPHSTROM will evaluate the clinical safety and efficacy of a next-generation cell therapy discovered by Galway-based Orbsen Therapeutics, to combat diabetic kidney disease. Find out more about the project at www.nephstrom.eu.

VISICORT abstract accepted for oral presentation at ESBB’s 2014 Annual Conference, Leipzig

VISICORT have had an abstract accepted for oral presentation at ESBB’s 2014 Annual Conference. The ESBB conference will take place in Leipzig, Germany from Tuesday 21st to Friday 24th October.

Read more

Launch of VISICORT

Welcome to the VISICORT Project.  We are very excited to be launching the project in April 2014.

Please follow us on facebook or twitter for more updates.